MetaStat Inc
OTC:MTST
MetaStat Inc
Other Items
MetaStat Inc
Other Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
MetaStat Inc
OTC:MTST
|
Other Items
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Other Items
-$2.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-134%
|
CAGR 10-Years
-14%
|
|
|
Danaher Corp
NYSE:DHR
|
Other Items
-$40m
|
CAGR 3-Years
67%
|
CAGR 5-Years
71%
|
CAGR 10-Years
45%
|
|
|
Waters Corp
NYSE:WAT
|
Other Items
-$39.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
15%
|
CAGR 10-Years
18%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Other Items
$10m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Other Items
-$1.7B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
N/A
|
|
MetaStat Inc
Glance View
MetaStat, Inc. engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Boston, Massachusetts. The company went IPO on 2008-02-13. The firm's platform technologies are based on the identification of a pathway for the development of metastatic disease in epithelial-based solid tumors. The company is developing two driver-based diagnostic product lines: MetaSite Breast and MenaCalc. Its MetaSite Breast and MenaCalc diagnostic product candidates are designed for patients based on their individual risk of metastasis. The MetaSite Breast test is applicable for early stage invasive breast cancer patients. The MenaCalc platform is a tissue-based quantitative immunofluorescence (QIF) assay applicable to a range of epithelial-based cancers, including breast, lung, colorectal and prostate.
See Also
What is MetaStat Inc's Other Items?
Other Items
0
USD
Based on the financial report for Feb 28, 2018, MetaStat Inc's Other Items amounts to 0 USD.
